NIH Reporter #5R01HL170198-03

Research Grant for TMEM16A in Human Airway Disease (NHLBI)

This opportunity is a research grant from the National Heart Lung and Blood Institute (NHLBI) focused on the role of TMEM16A in human airway diseases. - Government Buyer: - National Heart Lung and Blood Institute (NHLBI), part of the National Institutes of Health - Based in Saint Louis, Missouri - Products/Services Requested: - Multidisciplinary research on TMEM16A in human airway disease, with emphasis on cystic fibrosis and COPD - Research approaches may include molecular, structural, and cellular studies - OEMs and Vendors: - No specific OEMs or vendors are named, as this is a research grant (not a procurement of goods) - Unique or Notable Requirements: - Open to multidisciplinary research teams - No unique licensing or restriction requirements specified - Classified under CFDA code 93.838 (Lung Diseases Research) and NIGP code 10 (Schools of Medicine) - Estimated funding for the project is $623,138

Description

This is a research grant opportunity focusing on the role of TMEM16A in human airway disease, specifically targeting cystic fibrosis and COPD. The project involves multidisciplinary approaches including molecular, structural, and cellular studies. The funding is provided by the National Heart Lung and Blood Institute (NHLBI) with a total award amount of $623,138 for the fiscal year 2026. The project duration is from April 1, 2024, to March 31, 2028. The solicitation is open and active with a detailed proposal submission required.

View original listing